Monopar doses first patient with uPAR-targeted radiopharmaceutical MNPR-101-Lu

Monopar Therapeutics

First patient dosed under US compassionate use protocol for metastatic pancreatic cancer.
MNPR-101-Lu targets uPAR; infusion well-tolerated with no serious adverse reactions.
Patient's tumor showed uPAR expression via prior MNPR-101-Zr PET/CT imaging.
Two Phase 1 studies ongoing in Australia for MNPR-101-Zr (imaging) and MNPR-101-Lu (treatment).
Company believes this is the world's first dosing of a uPAR-targeted therapeutic radiopharmaceutical.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.